Goldman Sachs Raises PT on Abbvie (ABBV) to $52

April 29, 2013 10:45 AM EDT Send to a Friend
Get Alerts ABBV Hot Sheet
Price: $67.43 -0.72%

Rating Summary:
    12 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 25 | New: 51
Trade ABBV Now!
Join SI Premium – FREE
Goldman Sachs today maintained a Buy rating on Abbvie (NYSE: ABBV) and raised its price target to $52.00 (from $45.00). Analyst Jami Rubin said he had greater confidence in Humira growth and in Abbvie's pipeline.

"We estimate that in a best case scenario the late stage pipeline could add up to $6 bn in revenues by 2020, although most sell side estimates are far short of this figure. For example, key pipeline assets in Hep C, elagolix and daclizumab could generate over $5.5 bn at peak (exhibit 1) while we have only $3.3 bn in our total 2020 pipeline estimates. This does not include several products which are expected to enter Phase 3 later this year, including ABT-119," said Rubin.

For an analyst ratings summary and ratings history on Abbvie (NYSE: ABBV) click here. For more ratings news on Abbvie click here.

Shares of Abbvie closed at $45.84 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Goldman Sachs

Add Your Comment